The vision of Life Science Leader is to help facilitate connections and foster collaborations in pharma and med device development to get more life-saving and life-improving therapies to market in an efficient manner. Connect, Collaborate, Contribute
Issue link: https://lifescienceleadermag.epubxp.com/i/320415
OUTSOURCING INSIGHTS REPORT If you want to learn more about the report or about how to participate, please contact Nigel Walker, managing director, or Salvatore Fazzolari, director of client services, at Nice Insight by sending an email to niceinsight.survey@thatsnice.com . N . W A L K E R S . F A Z Z O L A R I 18 Survey Methodology: The Nice Insight Pharmaceutical and Biotechnology Survey is deployed to outsourc- ing-facing pharmaceutical and biotechnology executives on an annual basis. The 2013-2014 report includes responses from 2,337 participants. The survey is comprised of 240+ questions and randomly presents ~35 ques- tions to each respondent in order to collect baseline information with respect to customer awareness and cus- tomer perceptions of the top 100+ CMOs and top 50+ CROs servicing the drug development cycle. Five levels of awareness from "I've never heard of them" to "I've worked with them" factor into the overall customer aware- ness score. The customer perception score is based on six drivers in outsourcing: Quality, Innovation, Regula- tory Track Record, Affordability, Productivity and Reliability. In addition to measuring customer awareness and perception information on specifi c companies, the survey collects data on general outsourcing practices and preferences as well as barriers to strategic partnerships among buyers of outsourced services. LIFESCIENCELEADER.COM JUNE 2014 approximately 15 percent of the buying market, and specialty pharma accounts for the remaining 10 percent. SELECTING AN OUTSOURCING PARTNER FOR VACCINE PRODUCTION While quality and reliability consistently hold the top two positions among part- ner attributes, when it comes to selecting an outsourcing partner for vaccine pro- duction, the importance of productivity and innovation moves upwards, caus- ing a company's regulatory track record to shift to sixth position. In fact, when reviewing the companies most likely to be considered for an outsourced vaccine project, the top five companies scored best in quality, reliability, and productivity. This ranking makes sense, as reliabil- ity is directly linked to security in sup- ply, and productivity is directly linked to time-to-market. Security in supply is particularly important for routine vac- cines, whether they are childhood immu- nizations or, like the newer HPV vaccine, administered during adolescence. Time- to-market becomes a considerable issue when there is a surge in the need for a vaccine, such as the flu vaccine when a particularly bad strain hits or during times like the swine flu and bird flu out- breaks. As CMOs continue to be viewed as trusted partners in bringing drugs to market, their expansion into segments such as vaccine production will continue to add value to drug innovators in terms of product security, improved time-to- market, and increased capacity — all traits where the positive impact is passed on to the health of the consumer. L The Percentage of Vaccine Production Outsourcers from Each Buyer Group Rank of Outsourcing Drivers Big Pharma: 32% Biotech / Biologics: 27% Emerging Biotech / Biologics: 15% Emerging, Niche, or Start-Up Pharma: 15% Specialty Pharma: 11% Vaccine Outsourcing Overall Outsourcing 80% 77% 81% 79% 75% 81% 79% Quality Innovation Reliability Affordability Regulatory Productivity Overall CP Score Average Score Among the Top 5 CMOs for Vaccine Production 1 4 2 5 3 6 Quality Reliability Productivity Innovation Affordability Regulatory 1 6 2 5 4 3 By K. Hammeke AS OUTSOURCING RELATIONSHIPS EVOLVE, VACCINE PRODUCTION WILL CONTINUE TO SHIFT TO CMOS 0 6 1 4 _ R e p o r t s _ O I . i n d d 2 0614_Reports_OI.indd 2 5 / 2 1 / 2 0 1 4 1 1 : 5 4 : 1 2 A M 5/21/2014 11:54:12 AM